-
公开(公告)号：US20140213518A1
公开(公告)日：2014-07-31
申请号：US14072568
申请日：2013-11-05
申请人： 1149336 Ontario Inc.
发明人： Daniel J. Drucker
IPC分类号： C07K14/605
CPC分类号： A61K38/26 , A61K49/0008 , C07K14/605
摘要： The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
摘要翻译： 本发明涉及胰高血糖素相关肽及其用于预防或治疗涉及大肠的疾病的用途。 特别是现在已经证明，GLP-2的GLP-2和肽激动剂可引起大肠组织的增殖。 因此，本发明提供了在有需要的受试者中增殖大肠的方法。 此外，本发明的方法可用于治疗或预防大肠炎症状况，包括炎性肠病。
-
公开(公告)号：US20040198642A1
公开(公告)日：2004-10-07
申请号：US10829201
申请日：2004-04-22
申请人： 1149336 ONTARIO INC.
IPC分类号： A61K038/22
CPC分类号： A61K45/06 , A61K38/26 , A61K2300/00
摘要： The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination comprising a GLP-2 activity enhancer, and a GLP-1 activity inhibitor. The combination is useful particularly to treat gastrointestinal conditions such as small bowel syndrome, mucositis and Crohn's disease, and to suppress appetite, for instance to treat obesity.
摘要翻译： 使用GLP-1活性抑制剂增强GLP-2的作用。 用于治疗或抑制用于GLP-2治疗的医学病症，病症或疾病的医学用途，本发明提供了包含GLP-2活性增强剂和GLP-1活性抑制剂的药物组合。 该组合对于治疗诸如小肠综合征，粘膜炎和克罗恩病的胃肠道疾病以及抑制食欲，例如治疗肥胖症是有用的。
-
公开(公告)号：US20030158101A1
公开(公告)日：2003-08-21
申请号：US10042746
申请日：2002-11-20
申请人： 1149336 Ontario Inc.
发明人： Daniel J. Drucker
IPC分类号： A61K038/22
CPC分类号： A61K38/26 , C07K14/605
摘要： Glucagon-like peptide 2, a product of glucagon gene expression, and analogs of glucagon-like peptide 2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described.
摘要翻译： 胰高血糖素样肽2，胰高血糖素基因表达的产物和胰高血糖素样肽2的类似物已被鉴定为胃肠组织生长因子。 描述了它们对小肠和胰岛生长的影响。 描述了它们作为药物的制剂及其在治疗肠道疾病中的治疗用途。
-
公开(公告)号：US20160000857A1
公开(公告)日：2016-01-07
申请号：US14711032
申请日：2015-05-13
IPC分类号： A61K38/05
CPC分类号： A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinenmia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
摘要翻译： 本发明提供用于修饰和调节葡萄糖和脂质代谢的方法和组合物，通常用于降低胰岛素抵抗，高血糖症，高胰岛素血症，肥胖症，高脂血症，高脂蛋白血症（如乳糜微粒，VLDL和LDL），并调节体脂肪和 更一般地，脂质储备，更一般地，用于改善代谢障碍，特别是与糖尿病，肥胖和/或动脉粥样硬化相关的那些。
-
公开(公告)号：US20130203673A1
公开(公告)日：2013-08-08
申请号：US13794314
申请日：2013-03-11
IPC分类号： A61K38/26 , G01N33/483
CPC分类号： A61K38/26 , A61K38/00 , C07K14/605 , G01N33/4833
摘要： Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
摘要翻译： 胰高血糖素样肽2（胰高血糖素基因表达的产物）的类似物已被鉴定为肠组织生长因子。 描述了它们作为药物的制剂和治疗用于治疗小肠疾病的药物。
-
公开(公告)号：US20030109449A1
公开(公告)日：2003-06-12
申请号：US10295820
申请日：2002-11-18
申请人： 1149336 Ontario Inc.
IPC分类号： A61K038/17 , C07K014/435 , C07K007/08 , G01N033/574
CPC分类号： C07K14/605 , A61K38/00 , G01N2333/605 , Y02A50/471
摘要： Antagonists of glucagon-like peptide 2, have been identified. Their effects on the growth of gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonists of glucagon-like peptide 2.
-
公开(公告)号：US20150290295A1
公开(公告)日：2015-10-15
申请号：US14685363
申请日：2015-04-13
申请人： 1149336 Ontario Inc.
发明人： Daniel J. Drucker
IPC分类号： A61K38/26 , A61K49/00 , C07K14/605
CPC分类号： A61K38/26 , A61K49/0008 , C07K14/605
摘要： The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
摘要翻译： 本发明涉及胰高血糖素相关肽及其用于预防或治疗涉及大肠的疾病的用途。 特别是现在已经证明，GLP-2的GLP-2和肽激动剂可引起大肠组织的增殖。 因此，本发明提供了在有需要的受试者中增殖大肠的方法。 此外，本发明的方法可用于治疗或预防大肠炎症状况，包括炎性肠病。
-
8.发明授权公开(公告)号：US09044424B2
公开(公告)日：2015-06-02
申请号：US13951060
申请日：2013-07-25
IPC分类号： A61K38/02 , A61K38/05 , A61K38/55 , A61K31/00 , A61K31/155 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K45/06
CPC分类号： A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods for modification and regulation of glucose metabolism by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to increase the plasma half-life of glucagon-like peptide 1 (GLP-1) but not sufficient to suppress the immune system of the animal.
摘要翻译： 本发明提供了通过向动物施用治疗有效量的二肽基肽酶IV（DPIV）或其药学上可接受的盐的抑制剂或其药学上可接受的盐来修饰和调节葡萄糖代谢的方法，其中抑制剂具有抑制DPIV的Ki为10nM 或更少; 并且以足以增加胰高血糖素样肽1（GLP-1）的血浆半衰期的量施用抑制剂，但不足以抑制动物的免疫系统。
-
公开(公告)号：US20140178472A1
公开(公告)日：2014-06-26
申请号：US13951060
申请日：2013-07-25
IPC分类号： A61K38/05
CPC分类号： A61K38/05 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/675 , A61K31/69 , A61K31/702 , A61K38/005 , A61K38/28 , A61K38/55 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
摘要翻译： 本发明提供了用于改变和调节葡萄糖和脂质代谢的方法和组合物，通常降低胰岛素抵抗，高血糖症，高胰岛素血症，肥胖症，高脂血症，高脂蛋白血症（如乳糜微粒，VLDL和LDL），并调节体脂肪和 更一般地，脂质储备，更一般地，用于改善代谢障碍，特别是与糖尿病，肥胖和/或动脉粥样硬化相关的那些。
-
公开(公告)号：US20020123461A1
公开(公告)日：2002-09-05
申请号：US10060279
申请日：2002-02-01
申请人： 1149336 ONTARIO INC.
IPC分类号： A61K038/26 , A61K038/17
CPC分类号： A61K45/06 , A61K38/26 , A61K2300/00
摘要： The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination comprising a GLP-2 activity enhancer, and a GLP-1 activity inhibitor. The combination is useful particularly to treat gastrointestinal conditions such as small bowel syndrome, mucositis and Crohn's disease, and to suppress appetite, for instance to treat obesity.
摘要翻译： 使用GLP-1活性抑制剂增强GLP-2的作用。 用于治疗或抑制用于GLP-2治疗的医学病症，病症或疾病的医学用途，本发明提供了包含GLP-2活性增强剂和GLP-1活性抑制剂的药物组合。 该组合对于治疗诸如小肠综合征，粘膜炎和克罗恩病的胃肠道疾病以及抑制食欲，例如治疗肥胖症是有用的。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.018 秒)
